Medipost Closes In $140 Million Funding To Back Planned U.S. Phase III Trial
By Amit Chowdhry ● Jan 11, 2026
MEDIPOST, a Cambridge, Massachusetts-based biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies, said its parent company, MEDIPOST Co., Ltd., has closed $140 million in funding to accelerate late-stage clinical development and expand manufacturing and operational infrastructure.